Publications
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant.
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H., Saito, M., Adachi, E., Sullivan, D., Pekosz, A., Watanabe, S., Maeda, K., Imai, M., Yotsuyanagi, H., Mitsuya, H., … Kawaoka, Y. (2022). The New England Journal of Medicine, 386(10), 995-998.
The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions
McLean, A., Rashan, S., Tran, L., Arena, L., Lawal, A., Maguire, B., Adele, S., Antonio, E., Brack, M., Caldwell, F., Carrara, V., Charles, R., Citarella, B., Epie, T., Feteh, V., Kennon, K., Makuka, G., Ngu, R., Nwosu, A.-P., … Guérin, P. (2022). In Wellcome Open Research.
Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
Schilling, W., Jittamala, P., Watson, J., Ekkapongpisit, M., Siripoon, T., Ngamprasertchai, T., Luvira, V., Pongwilai, S., Cruz, C., Callery, J., Boyd, S., Kruabkontho, V., Ngernseng, T., Tubprasert, J., Abdad, M., Piaraksa, N., Suwannasin, K., Hanboonkunupakarn, P., Hanboonkunupakarn, B., … White, N. (2022). In medRxiv.
A multistage mixed-methods evaluation protocol for the national testing response during the COVID-19 pandemic in England
Naidoo, R., Lambert, B., Voysey, M., Shretta, R., Keene, C., Wanat, M., Andersen-Waine, B., Dahal, P., Stepniewska, K., Hounsell, R., Molyneux, S., Rowe, E., Pinto-Duschinsky, S., Yenidogan, G., Fowler, T., White, L., & the EY-Oxford Health Analytics Consortium. (2022). In medRxiv.
Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study of the ISARIC cohort
Wainstein, M., MacDonald, S., Fryer, D., Young, K., Young, K., Webb, S., Begum, H., Nichol, A., Lee, J., Balan, V., Cobb, P., Burrell, A., Kennon, K., Strudwick, S., Kelly, S., Semple, M., Merson, L., Murthy, S., Citarella, B., … The ISARIC Characterization Group. (2022). In medRxiv.
Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
Jittamala, P., Schilling, W., Watson, J., Luvira, V., Siripoon, T., Ngamprasertchai, T., Almeida, P., Ekkapongpisit, M., Cruz, C., Callery, J., Boyd, S., Anunsittichai, O., Hongsuwan, M., Singhaboot, Y., Pagornrat, W., Tuntipaiboontana, R., Kruabkontho, V., Ngernseng, T., Tubprasert, J., … White, N. (2022). In medRxiv.
An international observational study to assess the impact of the Omicron variant emergence on the clinical epidemiology of COVID-19 in hospitalised patients
Gonçalves, B., Hall, M., Jassat, W., Balan, V., Murthy, S., Kartsonaki, C., Semple, M., Rojek, A., Baruch, J., Reyes, L., Dasgupta, A., Dunning, J., Citarella, B., Pritchard, M., Martín-Quiros, A., Sili, U., Baillie, K., Aryal, D., Arabi, Y., … ISARIC Clinical Characterisation Group. (2022). In medRxiv.
Antibody Response to ChAdOx1-nCoV-19 Vaccine Among Recipients in Bangladesh: A Prospective Observational Study
Hoque, A., Barshan, A., Chowdhury, F., Fardous, J., Hasan, M., Khan, A., & Kabir, A. (2021). Infection and Drug Resistance, 14, 5491-5500.
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials
Axfors, C., Janiaud, P., Schmitt, A., van’t Hooft, J., Smith, E., Haber, N., Abayomi, A., Abduljalil, M., Abdulrahman, A., Acosta-Ampudia, Y., Aguilar-Guisado, M., Al-Beidh, F., Alejandria, M., Alfonso, R., Ali, M., AlQahtani, M., AlZamrooni, A., Anaya, J.-M., Ang, M., … Danielle, F. (2021). BMC Infectious Diseases, 21.
The value of open-source clinical science in pandemic response: lessons from ISARIC.
ISARIC Clinical Characterisation Group. Electronic address: james.lee@ndm.ox.ac.uk. (2021). The Lancet. Infectious Diseases, 21(12), 1623-1624.
Accessibility, inclusivity, and implementation of COVID-19 clinical management guidelines early in the pandemic: a global survey
Pilbeam, C., Malden, D., Newell, K., Dagens, A., Kennon, K., Michelen, M., Gobat, N., & Sigfrid, L. (2021). Wellcome Open Research, 6.
The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions
Schilling, W., Callery, J., Chandna, A., Hamers, R., Watson, J., & White, N. (2021). Wellcome Open Research, 6, 71-71.
A Middle-Aged Man Presented with Quadriparesis during COVID-19 Pandemic
Chowdhury, F., Paul, S., Aman, S., Haque, A., Rafiquzzaman, M., Rahman, M., & Chowdhury, F. (2021). Case Reports in Neurology, 13(2), 529-534.
Preprints in times of COVID19: the time is ripe for agreeing on terminology and good practices
Ravinetto, R., Caillet, C., Zaman, M., Singh, J., Guerin, P., Ahmad, A., Durán, C., Jesani, A., Palmero, A., Merson, L., Horby, P., Bottieau, E., Hoffmann, T., & Newton, P. (2021). BMC Medical Ethics, 22.
WHO COVID-19 therapeutic guidelines – authors' reply
White, N., Strub-Wourgaft, N., Faiz, A., & Guerin, P. (2021). Lancet, 398(10295), 118-118.
Acute Ischemic Stroke- A presenting feature of SARS-CoV-2 infection
Paul, S., Rahman, S., Chowdhury, F., Alam, R., & Chowdhury, F. (2021). Bangabandhu Sheikh Mujib Medical University Journal, 60-63.
Association of HLA-DRB1*09:01 with severe COVID-19.
Anzurez, A., Naka, I., Miki, S., Nakayama-Hosoya, K., Isshiki, M., Watanabe, Y., Nakamura-Hoshi, M., Seki, S., Matsumura, T., Takano, T., Onodera, T., Adachi, Y., Moriyama, S., Terahara, K., Tachikawa, N., Yoshimura, Y., Sasaki, H., Horiuchi, H., Miyata, N., … Kawana-Tachikawa, A. (2021). HLA, 98(1), 37-42.
Characterization of a new SARS-CoV-2 variant that emerged in Brazil.
Imai, M., Halfmann, P., Yamayoshi, S., Iwatsuki-Horimoto, K., Chiba, S., Watanabe, T., Nakajima, N., Ito, M., Kuroda, M., Kiso, M., Maemura, T., Takahashi, K., Loeber, S., Hatta, M., Koga, M., Nagai, H., Yamamoto, S., Saito, M., Adachi, E., … Kawaoka, Y. (2021). Proceedings of the National Academy of Sciences of the United States of America, 118(27), e2106535118.
Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis
Guérin, P., McLean, A., Rashan, S., Lawal, A., Watson, J., Strub-Wourgaft, N., & White, N. (2021).
Accessibility, inclusivity, and implementation of COVID-19 clinical management guidelines early in the pandemic: a global survey
Pilbeam, C., Malden, D., Newell, K., Dagens, A., Kennon, K., Michelen, M., Gobat, N., & Sigfrid, L. (2021).
Guidelines should not pool evidence from uncomplicated and severe COVID-19
White, N., Strub-Wourgaft, N., Faiz, A., & Guerin, P. (2021). Lancet, 397(10281), 1262-1263.
Continuous positive airway pressure (CPAP) as a ceiling of care treatment for hypoxaemic respiratory failure due to COVID-19.
Bradley, P., Nixon, J., Wilson, J., Redfern, J., Saba, T., Nuttall, E., & Bongers, T. (2021). Clinical Medicine (London, England), 21(Suppl 2), 21-22.
Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 patients reveals immune markers associated with disease severity and resolution.
Ravichandran, S., Lee, Y., Grubbs, G., Coyle, E., Klenow, L., Akasaka, O., Koga, M., Adachi, E., Saito, M., Nakachi, I., Ogura, T., Baba, R., Ito, M., Kiso, M., Yasuhara, A., Yamada, S., Sakai-Tagawa, Y., Iwatsuki-Horimoto, K., Imai, M., … Khurana, S. (2021). Science Advances, 7(10), eabf2467.
Antibody titers against SARS-CoV-2 decline, but do not disappear for several months
Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., Maeda, K., Kato, H., Nojima, M., Pattinson, D., Ogura, T., Baba, R., Fujita, K., Nagai, H., Yamamoto, S., Saito, M., … Kawaoka, Y. (2021). EClinicalMedicine, 32.
Seroconversion against SARS-CoV-2 occurred after the recovery in patients with COVID-19.
Yamamoto, S., Saito, M., Nagai, E., Toriuchi, K., Nagai, H., Yotsuyanagi, H., Nakagama, Y., Kido, Y., & Adachi, E. (2021). Journal of Medical Virology, 93(2), 692-694.